<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392337</url>
  </required_header>
  <id_info>
    <org_study_id>PTC02</org_study_id>
    <nct_id>NCT03392337</nct_id>
  </id_info>
  <brief_title>An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients</brief_title>
  <official_title>An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly
      for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 subjects will be treated with increasing doses of Narrowband Ultraviolet phototherapy
      three times weekly for 12 weeks. Patients will then be evaluated every 6 weeks through week
      36 to determine maintenance of response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis area severity index score</measure>
    <time_frame>12 weeks</time_frame>
    <description>PASI 75</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physicians Global Assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>PGA improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface Area</measure>
    <time_frame>12 weeks</time_frame>
    <description>BSA improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessments multiplied by Body surface area</measure>
    <time_frame>12 weeks</time_frame>
    <description>PGA x BSA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Open Label Narrowband UVB phototherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Narrowband UVB phototherapy for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narrowband UVB phototherapy</intervention_name>
    <description>Ultraviolet B phototherapy</description>
    <arm_group_label>Open Label Narrowband UVB phototherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adults ≥ 18 years of age.

          2. Diagnosis of chronic plaque-type psoriasis for at least 6 months

          3. Moderate to Severe plaque psoriasis as defined by BSA ≥10 PASI ≥12 IGA ≥3

          4. Able to give written informed consent prior to performance of any study related
             procedures

          5. Subject is able to attend Narrowband UVB phototherapy sessions three times a week and
             all other protocol specified visits

          6. Subject must be in general good health (except for psoriasis) as judged by the
             Investigator, based on medical history, physical examination.

        Exclusion Criteria:

          1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic,
             and/or guttate psoriasis) or drug induced psoriasis

          2. History of photosensitivity

          3. Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks or
             other experimental or commercially available biologic immune modulator(s) within 12
             weeks prior to the first IP dose.

          4. Use of any investigational drug within 4 weeks prior to randomization, or within 5
             pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).

          5. Use of oral systemic medications for the treatment of psoriasis within 4 weeks
             (includes, but not limited to, oral corticosteroids, methotrexate, acitretin,
             apremilast and cyclosporine).

          6. Patient used topical therapies to treat within 2 weeks of the Baseline Visit
             (includes, but not limited to, topical corticosteroids, vitamin D analogs, or
             retinoids).

          7. Initiated within 3 months, planned initiation of, or changes to, concomitant
             medications that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial
             drugs, lithium, ACE inhibitors ) during the trial

          8. Active infections requiring antibiotics in the 2 weeks prior to Baseline

          9. Patient received UVB phototherapy within 4 weeks of Baseline.

         10. Patient received PUVA phototherapy within 4 weeks of Baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerry Bagel, MD</last_name>
    <phone>6094434500</phone>
    <email>dreamacres1@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Nelson</last_name>
    <phone>6094434500</phone>
    <email>enelson@windsordermatology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Elise Nelson</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Bagel</last_name>
      <phone>609-443-4500</phone>
      <email>dreamacres1@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Elise Nelson</last_name>
      <phone>6094434500</phone>
    </contact_backup>
    <investigator>
      <last_name>Jerry Bagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian R Keegan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David S Nieves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

